drugset / Trial / NCT04600817

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

NCT04600817

Phase 2 Unknown 160 enrolled TJ Biopharma Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Timeline

Start
2020-12-31
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NT-I7 Protein / enzyme biologic

Indications